Target Price | $96.72 |
Price | $66.60 |
Potential |
45.23%
register free of charge
|
Number of Estimates | 25 |
25 Analysts have issued a price target Biomarin Pharmaceutical 2025 .
The average Biomarin Pharmaceutical target price is $96.72.
This is
45.23%
register free of charge
$127.00
90.69%
register free of charge
$65.00
2.40%
register free of charge
|
|
A rating was issued by 29 analysts: 22 Analysts recommend Biomarin Pharmaceutical to buy, 7 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Biomarin Pharmaceutical stock has an average upside potential 2025 of
45.23%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Billion $ | 2.42 | 2.82 |
18.16% | 16.50% | |
EBITDA Margin | 12.35% | 19.11% |
125.44% | 54.72% | |
Net Margin | 6.93% | 14.73% |
0.70% | 112.53% |
25 Analysts have issued a sales forecast Biomarin Pharmaceutical 2024 . The average Biomarin Pharmaceutical sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Biomarin Pharmaceutical EBITDA forecast 2024. The average Biomarin Pharmaceutical EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
21 Biomarin Pharmaceutical Analysts have issued a net profit forecast 2024. The average Biomarin Pharmaceutical net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | 0.88 | 2.18 |
17.33% | 147.73% | |
P/E | 30.57 | |
EV/Sales | 4.38 |
21 Analysts have issued a Biomarin Pharmaceutical forecast for earnings per share. The average Biomarin Pharmaceutical <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Biomarin Pharmaceutical stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Biomarin Pharmaceutical...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.